NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its quarterly earnings results on Monday, March, 5th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.04. The company earned $1.19 million during the quarter, compared to analyst estimates of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. The firm's revenue was up 290.2% compared to the same quarter last year. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

7 brokers have issued 12 month price targets for Syndax Pharmaceuticals' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $26.1667 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a drop in short interest in March. As of March 29th, there was short interest totalling 967,476 shares, a drop of 42.3% from the March 15th total of 1,676,430 shares. Based on an average daily volume of 352,354 shares, the short-interest ratio is presently 2.7 days. Currently, 5.6% of the company's stock are short sold.

Some companies that are related to Syndax Pharmaceuticals include CytomX Therapeutics (CTMX), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Flexion Therapeutics (FLXN), Uniqure (QURE), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), Inflarx (IFRX), Assembly Biosciences (ASMB), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Access Pharmaceuticals (ABEO), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX) and Mirati Therapeutics (MRTX).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Media stories about SNDX stock have trended positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.28 on Accern's scale. They also assigned media headlines about the company an impact score of 46.64 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $10.59.

Syndax Pharmaceuticals has a market capitalization of $253.15 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]